A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma
Status:
Terminated
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The study will compare the pharmacokinetic profile of OvaRex MAb-B43.13 ascites fluid product
and OvaRex MAb-B43.13 cell culture product. Safety and immune responses following treatment
with the cell culture product will be evaluated.